This presentation outlines work as part of MMV to develop a new class of antimalarials targeting dihydroorotate dehydrogenase (DHODH). The triazolopyrimidines were identified as lead compounds; information is provided on their mode of action, and their efficacy and pharmacokinetics in animal models.
Presentation from MMV 11th stakeholders’ meeting, Dar es Salaam, Tanzania, 2-3 June 2011. Medicines For Malaria Venture, Geneva, Switzerland; 18 pp.
DHODH: Structure-Guided Design of a New Class of Drugs